Paul Tudor Jones Immuno Gen, Inc. Transaction History

Tudor Investment Corp Et Al

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $1.07 Million - $2.56 Million	85,609 New	85,609 $2.54 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $1.04 Million - $1.51 Million	-232,719 Reduced 72.69%	87,428 $418,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $801,744 - $1.47 Million	-254,522 Reduced 44.29%	320,147 $1.44 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $137,857 - $242,060	32,361 Added 5.97%	574,669 $2.74 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $277,010 - $437,385	58,318 Added 12.05%	542,308 $4.02 Million

Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $497,968 - $653,708	99,197 Added 25.78%	483,990 $2.74 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $1.8 Million - $2.67 Million	310,721 Added 419.49%	384,793 $2.54 Million
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $481,468 - $779,978	74,072 New	74,072 $600,000
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $1.03 Million - $2.13 Million	-277,460 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.45 - $4.89 $734,584 - $1.04 Million	212,923 Added 329.92%	277,460 $999,000
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $214,262 - $344,627	64,537 New	64,537 $297,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $122,750 - $237,256	-18,321 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $92,887 - $145,102	18,321	18,321 $117,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.